RLAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Relay Therapeutics Inc (RLAY) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the stock has some positive momentum in the pre-market and bullish technical indicators, the company's weak financial performance, lack of recent news catalysts, and mixed analyst sentiment suggest caution. Additionally, the absence of strong trading signals from Intellectia Proprietary Trading Signals further supports a hold recommendation.
The technical indicators for RLAY are moderately positive. The MACD is above 0 and positively contracting, suggesting mild bullish momentum. The RSI is neutral at 60.808, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its R1 resistance level of 9.42, with key support at 8.511. However, the stock's short-term trend indicates a 60% chance of a slight decline (-1.31%) in the next day and -1.57% in the next week.
Hedge funds are significantly increasing their positions, with buying up 352.49% last quarter.
Analysts from Oppenheimer and Wells Fargo have recently upgraded the stock, citing potential for competitive data updates and a price target increase to $13-$
Bullish technical indicators and pre-market price increase of 2.51%.
Weak financial performance in Q4 2025, with net income down -27.78% YoY and EPS down -28.89% YoY.
Gross margin dropped to 0, indicating no profitability.
Lack of recent news or event-driven catalysts.
No recent trading activity from Congress or influential figures.
Stock trend analysis suggests potential short-term declines in price.
In Q4 2025, revenue remained flat at $7,000,000 YoY. Net income dropped significantly to -$54,890,000 (-27.78% YoY), and EPS declined to -0.32 (-28.89% YoY). Gross margin fell to 0, indicating no profitability. Overall, the company's financials show declining performance and no growth trends.
Analysts have recently upgraded the stock. Oppenheimer upgraded RLAY to Outperform with a $14 price target, citing potential tailwinds from gedatolisib's VIKTORIA-1 readout. Wells Fargo also upgraded the stock to Overweight with a $13 price target, citing competitive data updates. However, there is skepticism about the success of competing products, which could create opportunities for RLAY.
